Shopping Cart
- Remove All
- Your shopping cart is currently empty
BBT has anti-hyperglycemic activity, acting through cAMP/PKA and the persistent L-type voltage-dependent Ca2+ channels/CaMK2 pathways to protect β-cells from cytokine or streptozotocin (STZ)-induced cell death and restore β-cell function, used in studies of diabetes.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $33 | In Stock | |
25 mg | $68 | In Stock | |
50 mg | $108 | In Stock | |
100 mg | $172 | In Stock |
Description | BBT has anti-hyperglycemic activity, acting through cAMP/PKA and the persistent L-type voltage-dependent Ca2+ channels/CaMK2 pathways to protect β-cells from cytokine or streptozotocin (STZ)-induced cell death and restore β-cell function, used in studies of diabetes. |
In vitro | BBT stimulates insulin secretion in a glucose-dependent manner. BBT effectively reversed β cell death induced by treatment with STZ (0.4 mM) or cytokines (10 ng/ml TNF-α and 5 ng/ml IL1B) in a dose-dependent manner. BBT can reverse STZ or cytokine-induced GSIS defects. [1] |
In vivo | BBT (50 mg/kg/day intravenously for 4 weeks) improved glucose homeostasis in STZ/ HFD-induced type 2 diabetes mice. [1] |
Molecular Weight | 386.26 |
Formula | C18H12BrNO2S |
Cas No. | 445000-45-3 |
Smiles | O=C(NC=1C=CC=CC1C(=O)C=2C=CC=CC2)C=3SC(Br)=CC3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (258.89 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.